TY - JOUR
T1 - Impairment of antipyrine metabolism by low‐dose oral contraceptive steroids
AU - Abernethy, Darrell R.
AU - Greenblatt, David J.
PY - 1981/1
Y1 - 1981/1
N2 - The effect of low‐dose oral contraceptive steroids (OCS) on the kinetics of intravenous antipyrine was determined. Eight women (age, 23.1 ± 1.1 yr (x̄ ± SE); weight, 57.8 ± 2.2 kg) using low‐dose (≤ 50 µg) estrogen oral contraceptive steroids (OCS) on a long‐term basis were age‐ and weight‐matched with eight controls (age, 23.4 ± 0.8 yr; weight, 58.4 ± 2.1 kg) not using OCS. All were nonsmokers taking no other drugs. OCS subjects had a longer antipyrine elimination half‐life (t½β) than the controls (17.3 ± 1.6 and 10.5 ± 0.8 hr; p < 0.005). Volume of distribution was similar for both groups (0.59 ± 0.02 l/kg [OCS] and 0.58 ± 0.02 l/kg). Total metabolic clearance of antipyrine was slowed in OCS subjects (0.41 ± 0.03 and 0.66 ± 0.05 ml/min/kg; p < 0.001). Since volume of distribution and body weight are of the same order in both groups, prolongation of antipyrine t½β is the result of decreased total metabolic clearance. Thus, even low‐dose estrogen containing OCS may impair clearance of other drugs. Clinical Pharmacology and Therapeutics (1981) 29, 106–110; doi:
AB - The effect of low‐dose oral contraceptive steroids (OCS) on the kinetics of intravenous antipyrine was determined. Eight women (age, 23.1 ± 1.1 yr (x̄ ± SE); weight, 57.8 ± 2.2 kg) using low‐dose (≤ 50 µg) estrogen oral contraceptive steroids (OCS) on a long‐term basis were age‐ and weight‐matched with eight controls (age, 23.4 ± 0.8 yr; weight, 58.4 ± 2.1 kg) not using OCS. All were nonsmokers taking no other drugs. OCS subjects had a longer antipyrine elimination half‐life (t½β) than the controls (17.3 ± 1.6 and 10.5 ± 0.8 hr; p < 0.005). Volume of distribution was similar for both groups (0.59 ± 0.02 l/kg [OCS] and 0.58 ± 0.02 l/kg). Total metabolic clearance of antipyrine was slowed in OCS subjects (0.41 ± 0.03 and 0.66 ± 0.05 ml/min/kg; p < 0.001). Since volume of distribution and body weight are of the same order in both groups, prolongation of antipyrine t½β is the result of decreased total metabolic clearance. Thus, even low‐dose estrogen containing OCS may impair clearance of other drugs. Clinical Pharmacology and Therapeutics (1981) 29, 106–110; doi:
UR - http://www.scopus.com/inward/record.url?scp=0019516860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019516860&partnerID=8YFLogxK
U2 - 10.1038/clpt.1981.17
DO - 10.1038/clpt.1981.17
M3 - Article
C2 - 7460468
AN - SCOPUS:0019516860
SN - 0009-9236
VL - 29
SP - 106
EP - 110
JO - Clinical Pharmacology & Therapeutics
JF - Clinical Pharmacology & Therapeutics
IS - 1
ER -